# Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma Patients

> **NCT05603845** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 291 (actual)

## Conditions studied

- Severe Asthma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05603845
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-20
- **Primary completion:** 2025-04-10
- **Final completion:** 2025-04-10
- **Target enrollment:** 291 (ACTUAL)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05603845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05603845, "Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05603845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*